Price movement over the last 24 hours
Align Technology, Inc. vs ARK Innovation ETF — how do they compare? Align Technology, Inc. trades at $173.86 (market cap $13.27B), while ARK Innovation ETF trades at $80.05. Which is the better fit depends on your goals.
| ALGN | ARKK | |
|---|---|---|
Market Cap | $13.27B | — |
Sector | Health | — |
52-Week High | $207.19 | $92.50 |
52-Week Low | $124.88 | $63.52 |
Enterprise Value | $12.32B | — |
Signals from Pluang's Aura AI — not financial advice
ALGN trades at $185.22, up 0.38% today, with a bullish technical signal and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results expected soon. Revenue remains stable around $4.0B, supported by a 67.57% gross margin and positive cash flow trends. Recent news highlights global expansion and product innovation, including a new manufacturing facility in India.
Outlook is positive with a $220.75 consensus price target, though risks include regulatory scrutiny from the European Commission and competitive pressures. The stock's valuation at a P/E of 31.65 reflects growth expectations, but investors should monitor execution on international growth and demand stability in North America.
ARK Innovation ETF (ARKK) trades at $83.61, up 2.9% with a bullish technical outlook from moving averages. The ETF faces mixed sentiment with concerns about its 0.75% expense ratio and 37.88% five-year loss, though recent inflows and AI-focused portfolio shifts show renewed investor interest. Tesla's 10% weighting remains a key driver, while technical indicators show overbought short-term RSI but strong trend momentum.
Outlook hinges on ARKK's concentrated bets in disruptive innovation stocks amid AI momentum, but high fees and volatility pose risks. The ETF's performance remains tied to Tesla and Cathie Wood's stock-picking, with current technical strength suggesting near-term upside if support at $82 holds.
Trailing returns across standard periods
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →